Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal Microbiota Transplantation (Chinese University of Hong Kong)
- Development stage
- Unknown
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral
01
Overview
Fecal Microbiota Transplantation (FMT) is a microbial therapy developed by the Chinese University of Hong Kong (CUHK) for the treatment of moderate to severe *Clostridioides difficile* infection (CDI). The procedure involves the infusion of a processed suspension of fecal matter from a screened, healthy donor into the gastrointestinal tract of a recipient. This intervention aims to restore the diversity and functional stability of the recipient's gut microbiome, which provides colonization resistance against *C. difficile* through nutrient competition, restoration of bile acid metabolism, and production of antimicrobial substances. It is investigated as a first-line therapy for severe CDI and as a treatment for recurrent or refractory cases where standard antibiotic regimens, such as vancomycin, have failed.
- Other names
- fecal microbiota-Chinese University of Hong Kong-Clostridioides difficile infectionFMTFecal Microbiota TransplantationFecal Bacteriotherapy
Beyond the preview
Go deeper on Fecal Microbiota Transplantation (Chinese University of Hong Kong).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal Microbiota Transplantation (Chinese University of Hong Kong).